FAST Generics Act of 2017
Latest action · Apr 7, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 6, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Fair Access for Safe and Timely Generics Act of 2017 or the FAST Generics Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the license holder of a Food and Drug Administration (FDA)-approved drug or biological product from restricting availability of the medication for testing by a product developer seeking to develop a drug, generic drug, or biosimilar, including restricting availability with a risk evaluation and mitigation strategy (REMS).
Upon request, the license holder of a medication that is not subject to a REMS must provide a product developer with the medication for testing.
For a medication subject to a REMS, a product developer must have FDA authorization to obtain the medication before the license holder must provide it. The FDA may authorize a product developer to conduct testing and clinical trials with the medication.
A wholesaler or specialty distributor who receives a request from a product developer for a medication for testing may not disclose to the license holder the identity of the product developer.The FDA may prohibit or limit transfer of a medication to a product developer if the transfer poses an imminent hazard to public health.
License holders are not liable for claims arising from a product developer testing a medication.
The FDA may waive the requirement that a medication use a single, shared system of elements to assure safe use with a comparable approved medication if the product developer is unable to finalize terms for a shared system with the license holder of the approved medication.
Cosponsors 13
Members who signed on, in the order they did. Signatures ran from Apr 6, 2017 to Sep 27, 2018; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-VT | Peter Welch | Original | Apr 6, 2017 |
| D-CO | Diana DeGette | May 17, 2017 | |
| D-OR | Kurt Schrader | May 17, 2017 | |
| R-OH | Steve Stivers | May 17, 2017 | |
| D-IL | Daniel Lipinski | May 25, 2017 | |
| D-IL | Janice D. Schakowsky | Jun 2, 2017 | |
| R-NE | Jeff Fortenberry | Jun 2, 2017 | |
| R-OH | James B. Renacci | Jul 25, 2017 | |
| D-PA | Matt Cartwright | Oct 3, 2017 | |
| D-CA | Ro Khanna | Jul 26, 2018 | |
| D-NM | Michelle Lujan Grisham | Sep 7, 2018 | |
| R-OH | David P. Joyce | Sep 17, 2018 | |
| D-CA | Ami Bera | Sep 27, 2018 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 6, 2017 |
| Health Subcommittee | Referred Apr 7, 2017 |
Actions 3
Everything that happened, newest first.
- Apr 7, 2017Referred to the Subcommittee on Health.
- Apr 6, 2017Introduced in House
- Apr 6, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 60, April 6, 2017, page H2792.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| IF11075 | FDA and Drug Prices: Facilitating Access to Generic Drugs | Resource | Jan 17, 2019 |
| R44810 | FDA Risk Evaluation and Mitigation Strategies (REMS): Description and Effect on Generic Drug Development | Report | Mar 16, 2018 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
- Short Titles as Introduced
- FAST Generics Act of 2017
- Fair Access for Safe and Timely Generics Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 6, 2017Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.